*Only for reading and reference by medical professionals

Cross-field dialogue between gastric cancer, breast cancer , lung cancer, pathology and pharmacy experts
Antibody drug conjugates (ADCs) are one of the most active new drugs in the field of anti-tumor drug development today. From the concept of "magic bullet", after a hundred years, with the accumulation and development of technologies such as monoclonal antibodies, conjugation chemistry and new cytotoxic drug delivery, the ADC drug technology platform has gradually matured and become a hot spot for drug research and development, with high hopes. In particular, DS-8201 has achieved dazzling success and its breakthroughs in breast cancer, gastric cancer, lung cancer and other fields have once again pushed the research and development of ADC drugs into a new era. Currently, there are more than 160 ADC drugs in clinical development around the world.
Based on this, the ADC Academy platform hosted by the Beijing Science and Technology Innovation Medical Development Foundation hereby holds the "2022 Annual Review - ADC in Solid Tumor" conference to discuss new developments in anti-HER2 treatment of solid tumors and share insights. This conference specially invited Professor Li Jin, Professor Zhang Qingyuan, and Professor Yao Yu to serve as conference chairmen; Professor Li Su, Professor Li Qiu, Professor Zhang Jian, and Professor Duan Jianchun as conference speakers; Professor Nie Jianyun, Professor Niu Zuoxing, Professor Ma Rui, and Professor Zeng Xuan were invited as panellists.
A cross-field dialogue between breast cancer, gastric cancer, lung cancer, pathology and pharmacy experts will focus on the treatment progress of ADC drugs in corresponding fields in 2022, and analyze and interpret the new changes in clinical diagnosis and treatment brought about by this.
looks forward to your participation and support!
December 24 09:00-11:50

This article is only used to provide scientific information to medical professionals and does not represent the views of this platform